Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.55 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27977748 | 0.98 | KCNH2 (0.58) | KCNH2GPR84TDP1L3MBTL1KDM4E | |
| SCHEMBL27769288 | 0.98 | KCNH2 (0.58) | KCNH2GPR84TDP1L3MBTL1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28527210 | 0.96 | KCNH2 (0.56) | KCNH2GPR84TDP1L3MBTL1DGAT1 | |
| SCHEMBL14234022 | 0.89 | KCNH2 (0.41) | KCNH2GPR84TLR8KDM4E | |
| SCHEMBL20069351 | 0.87 | KCNH2 (0.42) | KCNH2GPR84TDP1L3MBTL1DGAT1 | |
| SCHEMBL28902630 | 0.87 | KCNH2 (0.50) | KCNH2TLR8PDPK1 | |
| SCHEMBL977515 | 0.87 | KCNH2 (0.42) | KCNH2GPR84TDP1L3MBTL1DGAT1 | |
| SCHEMBL12299418 | 0.82 | KCNH2 (0.47) | KCNH2 | |
| SCHEMBL27592765 | 0.82 | KDM4E (0.42) | KCNH2L3MBTL1TLR8KDM4E | |
| SCHEMBL16815234 | 0.81 | TLR8 (0.36) | KCNH2TDP1L3MBTL1DGAT1TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 612 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-06-04 | — | — | US | claimed |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2024-01-16 | — | — | US | claimed |
| EP-3122757-B1 | CHARGED LINKERS AND THEIR USES FOR CONJUGATION | HANGZHOU DAC BIOTECH CO LTD (CN) | 2023-09-06 | — | — | EP | claimed |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-08-03 | — | — | US | claimed |
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-06-01 | — | — | US | claimed |
| CN-116143678-A | Conjugate linker, cell-binding molecule-drug conjugate containing the same, and preparation and application thereof | 杭州多禧生物科技有限公司 | 2023-05-23 | — | — | CN | claimed |
| WO-2023078021-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | claimed |
| EP-4168009-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | Hangzhou DAC Biotech Co., Ltd. (CN) | 2023-04-26 | — | — | EP | claimed |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2023-04-13 | — | — | US | claimed |
| EP-2635300-A1 | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPY | IBC Pharmaceuticals, Inc. (US) | 2013-09-11 | — | — | EP | claimed |
| WO-2012061548-A1 | DOCK-AND-LOCK (DNL) CONSTRUCTS FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV) THERAPY | IBC PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | claimed |
| US-20120082685-A1 | Dock-and-Lock (DNL) Constructs for Human Immunodeficiency Virus (HIV) Therapy | IBC PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | US | claimed |
| CN-101486711-B | 2,3-diaryl pyrimidine [1,2-a]benzimidazole heterocyclic compound, preparation and use thereof | UNIV SHANXI NORMAL | 2011-07-06 | — | — | CN | claimed |
| CN-101343253-B | 2-amido-4, 5-diaryl miazines compound, preparation and pharmaceutical use thereof | UNIV SHANXI NORMAL | 2011-03-16 | — | — | CN | claimed |
| CN-101486711-A | 2,3-diaryl pyrimidine [1,2-a]benzimidazole heterocyclic compound, preparation and use thereof | UNIV SHANXI NORMAL (CN) | 2009-07-22 | — | — | CN | claimed |
| CN-101343253-A | 2-amido-4, 5-diaryl miazines compound, preparation and pharmaceutical use thereof | UNIV SHAANXI NORMAL (CN) | 2009-01-14 | — | — | CN | claimed |
| US-20080241289-A1 | PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | claimed |
| WO-2008103899-A1 | PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-08-28 | — | — | WO | claimed |
| US-20080039428-A1 | Antiretroviral combination therapy | PANACOS PHARMACEUTICALS, INC. (US) | 2008-02-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165931-A1 | A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS | TEKT1, CD2BP2, CD4 | KCNH2 4471/4885GPR84 1198/4885TDP1 2848/4885 |
| US-11873281-B2 | Conjugates of cell binding molecules with cytotoxic agents | CD4, CD2, CD47 | KCNH2 3937/4885GPR84 1835/4885TDP1 972/4885 |
| US-11998584-B2 | Conjugate of a tubulysin analog with branched linkers | TEKT1, TEK, CD2BP2 | KCNH2 4524/4885GPR84 1324/4885TDP1 2974/4885 |
| US-20230115871-A1 | A CONJUGATE OF A CYTOTOXIC AGENT TO A CELL BINDING MOLECULE WITH BRANCHED LINKERS | CD2BP2, EPCAM, CD74 | KCNH2 4577/4885GPR84 1662/4885TDP1 2280/4885 |
| US-20080241289-A1 | PREPARATION AND UTILITY OF NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | TYMP, POLRMT, POLR1E | KCNH2 4369/4885GPR84 4452/4885TDP1 64/4885 |
| US-20230241241-A1 | CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS | CD4, DCLRE1A, TOP1 | KCNH2 4765/4885GPR84 1567/4885TDP1 878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.